Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report-Reference-Cited by-同舟云学术

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

Published:2013-08-22 Issue:8 Volume:122 Page:1395-1398
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Tefferi Ayalew¹,Cervantes Francisco²,Mesa Ruben³,Passamonti Francesco⁴,Verstovsek Srdan⁵,Vannucchi Alessandro M.⁶,Gotlib Jason⁷,Dupriez Brigitte⁸,Pardanani Animesh¹,Harrison Claire⁹,Hoffman Ronald¹⁰,Gisslinger Heinz¹¹,Kröger Nicolaus¹²,Thiele Juergen¹³,Barbui Tiziano¹⁴,Barosi Giovanni¹⁵

Affiliation:

1. Mayo Clinic, Rochester, MN;

2. Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain;

3. Mayo Clinic, Scottsdale, AZ;

4. Ospedale di Circolo e Fondazione Macchi, Varese, Italy;

5. MD Anderson Cancer Center, Houston, TX;

6. University of Florence, Florence, Italy;

7. Stanford University School of Medicine, Stanford, CA;

8. Service d'Hématologie Clinique, Centre Hospitalier de Lens, Lens, France;

9. Department of Haematology, St. Thomas Hospital, London, United Kingdom;

10. Mount Sinai School of Medicine, New York, NY;

11. Medical University of Vienna, Vienna, Austria;

12. University Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Germany;

13. University of Cologne, Cologne, Germany;

14. Division of Hematology and Research Foundation, Ospedale Papa Giovanni XXIII, Bergamo, Italy; and

15. Center for the Study of Myelofibrosis, Biotechnology Research Area, Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation, Pavia, Italy

Abstract

Key Points Treatment response criteria for MF must capture drug benefit in terms of symptom burden. The current document includes stricter definitions of red cell transfusion need and independence.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/8/1395/1374459/1395.pdf

Reference22 articles.

1. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment [letter]. Leukemia.;Barosi,2008

2. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.;Cervantes;Blood,2009

3. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.;Mesa;Cancer,2007

Cited by 299 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study;Oncohematology;2024-09-01

2. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial;The Lancet Haematology;2024-09

3. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis;Annals of Hematology;2024-08-15

4. Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review;Expert Review of Hematology;2024-08-13

5. Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial;International Journal of Hematology;2024-08-07